Abstract submission

Submission Opening

15 February 2024

Submission Closing

1 October 2024

Acceptance Notification

Starting from 20 January 2025

Free Communications are brief presentations (oral or poster) on studies, investigations, or observations in dermatology, and represent a vital component of the Scientific Program of the ICD. All Free Communications abstracts must be submitted online through the ICD Congress website. Select “Online Abstract Submission” and follow the steps making sure to carefully complete all sections. If all sections are not completed, your abstract submission will NOT be accepted.
The presenting author MUST REGISTER FOR THE ICD BY 3 MARCH, 2025 before the abstract can be officially be accepted for inclusion in the final scientific program and the official abstract book.

For additional information, please contact: icd2025abstract@thetriumph.com

Guidelines for abstract submission (free communications)

Free Communications are brief presentations (oral or poster) on studies, investigations, or observations in dermatology, and represent a vital component of the Scientific Program of the ICD. All Free Communications abstracts must be submitted online through the ICD Congress website. Select “Online Abstract Submission” and follow the steps making sure to carefully complete all sections. If all sections are not completed, your abstract submission will NOT be accepted.

Rules for abstract submission

a) Authors are required to indicate their preference for either ORAL or POSTER presentation by checking the appropriate box on the submission web page. The ICD Free Communications Committee will make the final decision on the format of presentation (i.e. oral or poster). Few selected posters will be scheduled for short oral presentations.

b) Acceptance or rejection of abstracts will be based on rankings given by a peer review of experts in the associated topic/category. Results of the selection process will be sent via e-mail to the corresponding author. The Committee decision is final and cannot be appealed.

c) Abstracts cannot be identical to any abstract that has previously been presented at a major international meeting prior to the ICD2025. An update to prior study is acceptable.

d) Instructions on the preparation of posters and information about projection facilities will be included with the notification of acceptance.

e) Submission of an abstract indicates: • that the author(s) agree to comply with the abstract submission and presentation rules; • that the presentation is based on scientific and/or clinical methods that are ethical and valid; • that all authors have contributed to and approve the abstract and its entire contents.

f) All accepted abstracts will be published electronically on digital media and on the ICD2025 website, and distributed to all delegates.

g) Accepted abstracts are official communications of the Congress. The presenting author agrees to register, to attend the Congress, and to present the abstract as scheduled by the ICD. The presenting author MUST REGISTER FOR THE ICD BY 3 MARCH, 2025 before the abstract can officially be accepted for inclusion in the final scientific program and official abstract book.

h) The evaluation and scoring of the abstract (acceptance as poster or as oral communication, or rejection) will be made according to a number of criteria, including: • Scholarly and/or research validity • Educational value • Clarity of presentation • Potential impact on global dermatology

Instructions for abstract preparation

(Please refer to the Abstract Template for specific guidance on formatting that will be available by February 2024).

a) Abstracts must be written and presented in English. Abstracts that are not written in understandable English will be rejected and/or returned to the author(s) for revision.

b) Abstract must be uploaded in WORD format (.doc; .docx)

c) Title, author’s names, author’s affiliation, presenting author must be provided by filling the online form • Title: Use a concise descriptive title that indicates the content of the abstract. Please minimize the use of abbreviations in the title. Commercial trade names for drugs, devices, products, and services may NOT be used in the title. • Author: The initial letter of the name(s) and the full surname for each author must be provided. Do not include degrees or titles. • Affiliations: Each author should be listed by department, institution, city, and country.

d) The body of the abstract text should not exceed 300 WORDS. The online submission program will automatically not allow submissions that do not fit this requirement. Symbols including superscripts and subscripts can be entered in the online system.

e) The body of the abstract text must be formatted with the following sub-headings as appropriate. Each sub-heading should be formatted in bold text, begin on a new line, and followed by a colon and space (:). The text for each sub-section should begin immediately after the colon and space (see sample abstract below). For clinical or investigative studies: • Introduction: • Objective: • Materials and Methods: • Results: • Conclusions: For case reports or case series: • Background: • Observation: • Key message: It is NOT satisfactory to simply state that “The results will be discussed.” Only common and standard abbreviations may be used without definition. NO REFERENCES, TABLES, CHARTS OR IMAGES ARE ALLOWED. Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted. Drugs, devices, products, and services should be identified by generic name only within the abstract. The use of commercial drug names, brands and registered trademarks are strictly prohibited. No mention of pharmaceutical company names should be included in the abstract. Data must be given in units (International metric system is preferred) that are generally accepted in scientific publications. All co-authors must agree with the submitted results and conclusions, and consent to being listed as authors. Work involving humans or animals, or material derived from them must have been approved by an institutional ethics committee.

Abstract topics

  1. Acne, Hidradenitis Suppurativa, Rosacea
  2. Aesthetic & Cosmetic Dermatology
  3. Artificial Intelligence & Skin Imaging
  4. Atopic Dermatitis
  5. Autoimmune Blistering Diseases
  6. Climate Change
  7. Contact Dermatitis
  8. Cutaneous Adverse Reactions to Drugs
  9. Cutaneous Oncology
  10. Dermatologic Surgery
  11. Dermatopathology
  12. Dermoscopy
  13. Gender Dermatology
  14. Genodermatoses
  15. Hair Disorders & Trichoscopy
  16. Lasers
  17. Medical Dermatology
  18. Migrant Health
  19. Mucosal Diseases
  20. Nail Disorders
  21. Novel Therapies
  22. Pediatric Dermatology
  23. Psychodermatology
  24. Photobiology & Phototherapy
  25. Physical Therapies (including PDT)
  26. Pigmentary Disorders
  27. Pruritus & Dysesthesias
  28. Psoriasis
  29. Sexually Transmitted Infections and HIV
  30. Skin Aging: Extrinsic and Intrinsic Factors
  31. Skin Infections & Tropical Diseases
  32. Skin of Color
  33. Teledermatology
  34. Urticaria & Angioedema
  35. Vasculitis & Vasculopathies
  36. Wound Healing & Keloids
  37. Miscellaneous

    Late-breaking abstracts

Important deadlines

Online Abstract Submission will be available on the Congress website until 1 October, 2024. Please follow the instructions detailed on the website. Your abstract submission will be acknowledged automatically by e-mail, but this confirmation does not constitute official acceptance for presentation.

Submitted abstract can be modified until 1 October, 2024 (abstract submission deadline). Please remove the abstract previously submitted and upload the new document. Authors who wish to withdraw their abstract must send a written request to: icd2025abstract@thetriumph.com

Download Abstract Guidelines Download Abstract Template

Keep in touch

Subscribe to our newsletter to stay up to date about ICD2025